Evidence map›Paper›PMID 39372513›Full record

ArticleApplied biosafety : journal of the American Biological Safety Association2024

Progress and Prospects for a Nucleic Acid Screening Test Set.

Nicole E Wheeler, Craig Bartling, Sarah R Carter, Adam Clore, James Diggans, Kevin Flyangolts, Bryan T Gemler, Brittany Rife Magalis, Jacob Beal

Abstract read
In one paragraph

Article in Applied biosafety : journal of the American Biological Safety Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. The evolution of the United States nucleic acid screening policies.Frontiers in bioengineering and biotechnology · 2026
    Review
  2. Developing a standard definition for sequences of concern.Frontiers in bioengineering and biotechnology · 2026
    Article
  3. Article
  4. Article
  5. The Case for Limiting "Sequences of Concern" to Those with Demonstrated Pathogenic Function.Applied biosafety : journal of the American Biological Safety Association · 2025
    Article
  6. Article
  7. Review
  8. Why implementation gaps could undermine synthetic nucleic acid oversight.Frontiers in bioengineering and biotechnology · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nicole E WheelerInstitute of Microbiology and Infection, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0003-4599-9164
Craig BartlingBattelle Memorial Institute, Columbus, Ohio, USA.
Sarah R CarterScience Policy Consulting LLC, Arlington, Virginia, USA.
Adam CloreIntegrated DNA Technologies Inc., Coralville, Iowa, USA.
James DiggansTwist Bioscience Corporation, South San Francisco, California, USA.ORCID https://orcid.org/0000-0003-3871-2380
Kevin FlyangoltsAclid Inc, New York, New York, USA.
Bryan T GemlerBattelle Memorial Institute, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-9635-4545
Brittany Rife MagalisDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
Jacob BealRaytheon BBN Technologies, Arlington, Virginia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: DNA synthesis companies screen orders to detect controlled sequences with misuse risks. Assessing screening accuracy is challenging owing to the breadth of biological risks and ambiguities in risk definitions. Here, we detail an International Gene Synthesis Consortium working group's rationale and process to develop a prototype DNA synthesis screening test dataset, aiming to establish a baseline of screening system accuracy to compare with various screening approaches. Methodology: Construction of the prototype test dataset involved four tool developers screening nucleic acid sequences from three taxonomic clusters of controlled organisms ( Results: The process highlighted several long-standing challenges in DNA synthesis screening, including the qualitative differences in approaches taken by screening tools. Our findings highlight the lack of clarity in assessing pathogen sequences with respect to regulatory control language, compounded by scientific uncertainty. We illustrate the current degree of consensus and existing challenges using classification statistics and specific examples. Conclusions and Next Steps: This prototype underscores the necessity of expert-regulator coordination in assessing gene-associated risks, offering a template for creating test sets across all taxonomic groups on international control lists. Expanding the working group would enrich dataset comprehensiveness, enabling a transition from species-focused to function-focused regulatory controls. This sets the foundation for quality control, certification, and improved risk assessment in DNA synthesis screening.

Indexed as

Australia groupbiosecurityexport controlsnucleic acid synthesisstandardssynthetic DNA

Identifiers

PMID39372513
PMCPMC11447130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.